![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 7
2017
Metzgeroth, G.; Schwaab, J.; Naumann, N.; Haferlach, C.; Jawhar, M.; Horny, H.-P.; Dirk, J.; Kratz-Albers, K.; Krämer, D.; Mayer, S.; Storch, N.; Burchert, A.; Haferlach, T.; Cross, N. C. P.; Hofmann, W.-K.; Fabarius, A. und Reiter, A.
(2017):
Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia.
In: Oncology Research and Treatment, Bd. 40: S. 196
2016
Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C. und Reiter, A.
(2016):
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 1: S. 136-143
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 12: S. 2342-2350
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H. P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C.; Fabarius, A.; Hofmann, W. K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis.
In: Haematologica, Bd. 101: S. 559
Jawhar, M.; Schwaab, J.; Meggendorfer, M.; Naumann, N.; Kluger, S.; Horny, H.-P.; Sotlar, K.; Haferlach, T.; Fabarius, A.; Hofmann, W.-K.; Reiter, A. und Metzgeroth, G.
(2016):
Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors.
In: Oncology Research and Treatment, Bd. 39: S. 24
Naumann, N.; Jawhar, M.; Schwaab, J.; Metzgeroth, G.; Khaled, N.; Horny, H.-P.; Sotlar, K.; Valent, P.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Meggendorfer, M.; Cross, N. C. P.; Hofmann, W. K.; Reiter, A. und Fabarius, A.
(2016):
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 25
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 232